Novartis's pelacarsen fails cardiovascular outcomes trial in Phase 3 studySep 4Clinical readoutIonis PharmaceuticalsNovartis
Ionis posts Q2 2026 results, flags second-half pipeline milestonesJul 29Quarterly updatedonidalorsenIonis Pharmaceuticals
Novartis posts pelacarsen Phase 3 apheresis results, updates three drug labelsJul 17Weekly roundup, 8 itemscarbamazepineimatinib
Sign inSign in